Literature DB >> 27470535

Plasma Leptin in Patients at Intermediate to High Cardiovascular Risk With and Without Type 2 Diabetes Mellitus.

Martina Montagnana1, Cristiano Fava2, Giovanni Targher3, Massimo Franchini4, Elisa Danese1, Sara Bonafini2, Angela De Cata3, Gian Luca Salvagno1, Orazio Ruzzenente1, Gian Cesare Guidi1, Giuseppe Lippi1.   

Abstract

BACKGROUND: A number of clinical studies have demonstrated that leptin concentrations are related to the metabolic disturbances that constitute the metabolic syndrome (MetS) and to diabetes mellitus (DM). AIM: To investigate possible determinants of leptin concentrations in a sample of patients at high cardiovascular (CV) risk carrying two or more features of the MetS and to investigate if any difference exist between at risk patients with or without DM.
METHODS: Serum leptin concentrations were measured in 60 consecutive male patients affected by at least two CV risk factors which belong to the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) definition of MetS: 30 patients affected by type 2 DM (T2DM) and 30 nondiabetic patients (non-T2DM). Nineteen healthy subjects were included in the study as a control group (HC).
RESULTS: Leptin was significantly higher in patients carrying two or more features of the MetS compared with HC (P = 0.02). Stratifying MetS patients for DM, we found that leptin level was higher in non-T2DM patients (7.8 ng/ml), intermediate in T2DM (6.2 ng/ml), and lower in HC (4.6 ng/ml). In MetS patients, a positive correlation was found between leptin and waist, triglycerides, and number of MetS criteria. After stratification for T2DM, the correlations were still significant in the non-T2DM but not in the T2DM group.
CONCLUSIONS: In our sample of moderate-to-high-risk patients, leptin level is positively associated with waist circumference and triglycerides but only in non-T2DM patients. Our data suggest that diabetic subjects could modulate leptin production in a different way compared with patients carrying other MetS-related anomalies.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  MetS; cardiovascular risk; diabetes mellitus; leptin; metabolic syndrome

Mesh:

Substances:

Year:  2016        PMID: 27470535      PMCID: PMC6817253          DOI: 10.1002/jcla.22031

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  54 in total

Review 1.  2. Classification and Diagnosis of Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2016-01       Impact factor: 19.112

2.  Low plasma leptin levels in well controlled type 2 diabetes are not related to body fat mass and whole-body insulin resistance.

Authors:  G Annuzzi; R Giacco; L Patti; L Bozzetto; D Viscovo; A A Rivellese
Journal:  Nutr Metab Cardiovasc Dis       Date:  2008-05-09       Impact factor: 4.222

3.  High plasma immunoreactive leptin level in essential hypertension.

Authors:  J Agata; A Masuda; M Takada; K Higashiura; H Murakami; Y Miyazaki; K Shimamoto
Journal:  Am J Hypertens       Date:  1997-10       Impact factor: 2.689

Review 4.  Clinical endocrinology of human leptin.

Authors:  L F Van Gaal; M A Wauters; I L Mertens; R V Considine; I H De Leeuw
Journal:  Int J Obes Relat Metab Disord       Date:  1999-02

5.  Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity.

Authors:  Paul W Franks; Soren Brage; Jian'an Luan; Ulf Ekelund; Mushtaquar Rahman; I Sadaf Farooqi; Ian Halsall; Stephen O'Rahilly; Nicholas J Wareham
Journal:  Obes Res       Date:  2005-08

6.  Leptin and lipid metabolism in chronic kidney failure.

Authors:  H Kastarinen; Y A Kesäniemi; O Ukkola
Journal:  Scand J Clin Lab Invest       Date:  2009       Impact factor: 1.713

7.  The lost correlation between leptin and CRP in type 2 diabetes.

Authors:  Afsaneh Morteza; Manouchehr Nakhjavani; Firuzeh Asgarani; Azam Ghaneei; Alireza Esteghamati; Hossein Mirmiranpour
Journal:  Eur Cytokine Netw       Date:  2013-03       Impact factor: 2.737

8.  Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.

Authors:  Y Miyazaki; R A DeFronzo
Journal:  Diabetes Obes Metab       Date:  2008-05-12       Impact factor: 6.577

9.  Leptin concentrations are associated with higher proinsulin and insulin concentrations but a lower proinsulin/insulin ratio in non-diabetic subjects.

Authors:  S M Haffner; H Miettinen; L Mykkänen; M P Stern
Journal:  Int J Obes Relat Metab Disord       Date:  1998-09

10.  Association of serum leptin levels with homeostasis model assessment-estimated insulin resistance and metabolic syndrome: the key role of central obesity.

Authors:  Alireza Esteghamati; Omid Khalilzadeh; Mehdi Anvari; Armin Rashidi; Mohammad Mokhtari; Manouchehr Nakhjavani
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

View more
  2 in total

Review 1.  In middle-aged and old obese patients, training intervention reduces leptin level: A meta-analysis.

Authors:  Ildikó Rostás; László Pótó; Péter Mátrai; Péter Hegyi; Judit Tenk; András Garami; Anita Illés; Margit Solymár; Erika Pétervári; Ákos Szűcs; Andrea Párniczky; Dániel Pécsi; Zoltán Rumbus; Csaba Zsiborás; Nóra Füredi; Márta Balaskó
Journal:  PLoS One       Date:  2017-08-15       Impact factor: 3.240

Review 2.  Temporal Leptin to Determine Cardiovascular and Metabolic Fate throughout the Life.

Authors:  Jae Geun Kim; Byung Ju Lee; Jin Kwon Jeong
Journal:  Nutrients       Date:  2020-10-24       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.